Research
Hormonal
Glucagon-like peptide (GLP-1) receptor agonists may induce generalized weight loss but may not effectively target visceral abdominal fat.
GLP-1 receptor agonists may not be the best choice for targeting visceral fat in HIV patients.
StrongQualifiesmedium confidence
GLP-1 receptor agonists, which induces generalized weight loss in a nonspecific way.
Why this rating
The abstract provides evidence from case presentations regarding the effects of GLP-1.
Source
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Robin Beach et al. · Clinical Infectious Diseases · 2026
DOI 10.1093/cid/ciag121
case_study · n=2Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →